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Abstract
Aims/hypothesis Recent studies suggest that abnormal function in Müller glial cells plays an important role in the pathogenesis
of diabetic retinopathy. This is associated with the selective accumulation of the acrolein-derived advanced lipoxidation end-
product, Nε-(3-formyl-3,4-dehydropiperidino)lysine (FDP-lysine), on Müller cell proteins. The aim of the current study was to
identify more efficacious acrolein-scavenging drugs and determine the effects of the most potent on Müller cell FDP-lysine
accumulation and neuroretinal dysfunction during diabetes.
Methods An ELISA-based in vitro assay was optimised to compare the acrolein-scavenging abilities of a range of drugs. This
identified 2-hydrazino-4,6-dimethylpyrimidine (2-HDP) as a new and potent acrolein scavenger. The ability of this agent to modify
the development of diabetic retinopathywas tested in vivo.Male SpragueDawley rats were divided into three groups: (1) non-diabetic;
(2) streptozotocin-induced diabetic; and (3) diabetic treated with 2-HDP in their drinking water for the duration of diabetes. Liquid
chromatography high-resolution mass spectrometry was used to detect 2-HDP reaction products in the retina. Immunohistochemistry,
real-time quantitative (q)RT-PCR and electroretinography were used to assess retinal changes 3 months after diabetes induction.
Results 2-HDP was the most potent of six acrolein-scavenging agents tested in vitro (p < 0.05). In vivo, administration of 2-HDP
reducedMüller cell accumulation of FDP-lysine at 3months in rats rendered diabetic with streptozotocin (p < 0.001). A 2-HDP adduct
was identified in the retinas of diabetic animals treated with this compound. 2-HDP supplementation was associated with reduced
Müller cell gliosis (p < 0.05), reduced expression of the oxidative stress marker haem oxygenase-1 (p < 0.001) and partial normalisa-
tion of inwardly rectifying K+ channel 4.1 (Kir4.1) expression (p < 0.001 for staining in perivascular regions and the innermost region
of the ganglion cell layer). Diabetes-induced retinal expression of inflammatory markers, inflammatory signalling compounds and
activation of retinal microglial cells were all reduced in 2-HDP-treated animals. Retinal neurophysiological defects in diabetic animals,
as indicated by changes in the electroretinogram 7weeks after induction of diabetes, were also reduced by 2-HDP (p < 0.05–0.01 for b-
wave amplitudes at flash intensities from −10 to +10 dB; p < 0.01 for time to peak of summed oscillatory potentials at +10 dB).
Conclusions/interpretation These findings support the hypothesis that Müller cell accumulation of FDP-lysine plays an impor-
tant role in the development of diabetic retinopathy. Our results also suggest that 2-HDP may have therapeutic potential for
delaying or treating this sight-threatening complication.
Keywords Acrolein . Advanced lipoxidation end-products . Diabetic retina . Electroretinography . Hydrazino compounds .
Inflammatory signalling .Müller glia . Oxidative stress . Retinopathy . Scavenging agents
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Abbreviations
ACR Acrolein
ALDH1A1 Aldehyde dehydrogenase 1A1
2-AP 2-Aminopropanol
DPH 1,2-Diphenylhydrazine
ERG Electroretinogram
FDP-lysine Nε-(3-formyl-3,4-dehydropiperidino)lysine
GFAP Glial fibrillary acidic protein
2-HDP 2-Hydrazino-4,6-dimethylpyrimidine
HDZ Hydralazine
HO-1 Haem oxygenase-1
2-HQ 2-Hydrazinoquinoline
HSA Human serum albumin
IBA1 Ionised calcium-binding adapter molecule 1
Kir4.1 Inwardly rectifying K+ channel 4.1
MESNA 2-Mercaptoethane sulfonate
m/z Mass-to-charge ratio
NAC N-acetyl-L-cysteine
qRT-PCR Real-time quantitative reverse transcriptase
PCR
RAGE Receptor for advanced glycation end-products
STZ Streptozotocin
S100B S100 calcium-binding protein B
Introduction
Diabetic retinopathy is a leading cause of newly diagnosed
blindness in people of working age in industrialised nations
[1]. Although there is no question that microvascular pathol-
ogy is central to the development of this condition, in recent
years it has become increasingly clear that diabetes also sig-
nificantly impacts neuronal and glial cell function in the retina
[2, 3]. Müller cells, which are the principal glial cells of the
retina and span its entire thickness, are known to be particu-
larly vulnerable to damage in diabetes. Positioned between the
retinal neurons and blood vessels, these cells normally play a
fundamental role in providing structural and neurotrophic sup-
port to the retina, regulating retinal metabolism, water, ion and
neurotransmitter homeostasis and matching retinal blood flow
to changes in neuronal activity (functional hyperaemia) [4]. In
diabetes, many of these important functions become disturbed
and the cells assume a reactive phenotype characterised by the
upregulation of glial fibrillary acidic protein (GFAP) and the
production of inflammatory chemokines and cytokines [5].
Given the importance of Müller cells in maintaining
neurovascular structure and function in the retina, their dys-
function in diabetes is believed to be a major factor that
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contributes to the evolution of the microvascular and neuro-
degenerative lesions of diabetic retinopathy [6, 7].
While considerable progress has been achieved in defining
the nature ofMüller cell abnormalities during diabetic retinop-
athy, less is known about the exact biochemical and molecular
mechanisms through which diabetes affects these cells.
Recent evidence from our laboratory, however, has suggested
that accumulation of the acrolein (ACR)-derived protein ad-
duct, Nε-(3-formyl-3,4-dehydropiperidino)lysine (FDP-ly-
sine), on Müller cell proteins may play a significant role [8,
9]. Selective accumulation of FDP-lysine is observed in
Müller cells within just a few months of experimental diabetes
and, when modelled in vitro, initiates Müller cell dysfunction
consistent with that observed in the diabetic retina, including
the induction of oxidative stress, generation of inflammatory
mediators and disruption of ionic homeostatic mechanisms
[9]. We have also reported that when administered at high
concentrations, the carbonyl-scavenging drug, pyridoxamine,
is moderately effective at reducing FDP-lysine formation and
Müller cell dysfunction in diabetic rodents [8]. However, we
have also found that pyridoxamine has deleterious effects on
the electroretinogram (ERG) in diabetic animals [10], raising
concerns about the potential usefulness of this drug for the
long-term treatment of diabetic retinopathy.
It is evident from these previous studies that targeting
Müller cell ACR/FDP-lysine accumulation could provide
new avenues for preventing neurovascular pathology during
diabetic retinopathy. Drugs capable of efficiently blocking
their formation in the absence of any adverse effects have
yet to be identified. 2-Mercaptoethane sulfonate (MESNA)
is an extremely potent thiol-based scavenger of ACR that is
used as an adjunctive therapy, along with alkylating chemo-
therapy drugs [11]. Although effective as a treatment for acute
ACR toxicity resulting from the metabolism of these agents,
the hydrophilicity of MESNA prevents it from readily enter-
ing cells, making it unsuitable for the routine sequestering of
Müller cell ACR within the eye [12]. Besides MESNA, the
hydrazino compound hydralazine (HDZ) has been identified
as an effective ACR scavenger [13]. HDZ has been approved
clinically as an anti-hypertensive drug for many years [14],
but its cardiovascular actions complicate its potential use for
the treatment of diabetic retinopathy. As it is the hydrazine
groups on hydralazine that are known to be responsible for
its ACR-scavenging abilities [15] and not all hydrazine-
containing compounds lower blood pressure [16], other com-
pounds containing hydrazino groups could have therapeutic
value for preventing Müller cell ACR/FDP-lysine accumula-
tion and dysfunction in diabetes.
In the present study, we screened a small panel of
hydrazino and other nucleophilic compounds for their ability
to scavenge ACR and compared our results with those obtain-
ed using MESNA and HDZ. Subsequently, we tested the ef-
fects of the most potent compound, 2-hydrazino-4,6-
dimethylpyrimidine (2-HDP), on Müller cell FDP-lysine ac-
cumulation and neuroretinal dysfunction in diabetic rodents.
Methods
Diabetic rat model All experiments were conducted in accor-
dance with the National Institutes of Health (NIH) Guide for
the Use and Care of Laboratory Animals (8th edition, 2011)
and approved by the Queen’s University of Belfast Animal
Welfare and Ethical Review Body. Work adhered to
Department of Health, Social Services and Public Safety
(DHSSPS)/Home Office project licence PPL2654.
Animals were assigned to experimental groups by simple
randomisation. Male Sprague Dawley rats (7–8 weeks of age;
~200 g body weight; Harlan, Bicester, UK) were rendered
diabetic by a single intraperitoneal injection of streptozotocin
(STZ; Sigma-Aldrich, Poole, UK; 65 mg/kg in 0.1 mol/l cit-
rate buffer, pH 4.6). Citrate-buffer-injected age-matched rats
were used as the control group. One week after STZ injection,
blood glucose measurements were made by glucometric as-
sessment of tail-prick blood samples (Breeze2, Bayer
Scientific, Leverkusen, Germany). Animals with blood glu-
cose concentrations >15 mmol/l were used in the study and
a subset of these diabetic animals received the ACR-
scavenging drug, 2-HDP (synthesised to >97% purity by
Fartop, Nanjing, China) administered orally in their drinking
water (dissolved directly at 100 mg/l). All animals were
housed in standard cages under a 12 h light–dark cycle in
the Biological Services Unit (BSU) at Queen’s University
Belfast with free access to food and water. Animal weights
and water consumption were monitored daily. At 3 months’
diabetes duration, rats were euthanised by CO2 asphyxiation
and blood collected via cardiac puncture for measurement of
HbA1c levels (GLYCO-Tek kit, Helena Biosciences Europe,
Gateshead, UK). No adverse events were associated with the
2-HDP intervention. No specific blinding was carried out to
outcome assessment.
ELISA for drug scavenging of ACR We developed an ELISA
assay to assess the ability of a small panel of hydrazino and
other nucleophilic compounds to scavenge ACR and prevent
FDP-lysine adduct formation on the model protein, human
serum albumin (HSA). The selected compounds had no
known cardiovascular actions [16] but retained drug-like
physiochemical properties (according to Lipinski’s rule of
five) [17]. The known ACR-scavenging drugs, HDZ and
MESNA, were included for comparison. Chemicals were pur-
chased from the following companies: HDZ, MESNA, 1,2-
diphenylhydrazine (DPH) and 2-aminopropanol (2-AP) from
Sigma-Aldrich; 2-HDP from Chembridge Corporation (San
Diego, CA, USA) and 2-hydrazinoquinoline (2-HQ) from
Fluorochem (Hadfield, UK). Full details of the ELISA are
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provided in the electronic supplementary material (ESM)
Methods.
Müller cell viability The RealTime-Glo MTcell viability assay
(Promega, Southampton, UK) was used to measure the effect
of ACR on primary Müller cell survival in the absence and
presence of 2-HDP. Full details of the assay are provided in
the ESM Methods.
Confocal immunolabelling Immunofluorescent staining of ret-
inal cryosections was performed as previously described [5,
8]. Retinal sections were stained for FDP-lysine, GFAP, haem
oxygenase-1 (HO-1), inwardly rectifying K+ channel 4.1
(Kir4.1), receptor for advanced glycation end-products
(RAGE), S100 calcium-binding protein B (S100B) and
ionised calcium-binding adapter molecule 1 (IBA1). The pri-
mary and secondary antibodies used are listed in ESM Table
1. Full details of the confocal immunolabelling methods are
provided in the ESM Methods.
Liquid chromatography high-resolution mass spectrometry
Diabetic rats administered clean drinking water (control) or
water containing 2-HDP (100 mg/l) were killed after 1 week,
their retinas dissected, flash frozen and extracted with metha-
nol. Extracted samples were dried, reconstituted in water and
analysed with a Waters ACQUITY I-Class ultra-high perfor-
mance liquid chromatography (UHPLC) system (Milford,
MA, USA) coupled to a Waters Xevo G2-XS QTOF mass
spectrometer (Manchester, UK) in the mass-to-charge ratio
(m/z) range 50–1200. Full details of the liquid chromatogra-
phy high-resolution mass spectrometry (LC-HRMS) method
are provided in the ESM Methods.
Quantitative RT-PCR Real-time quantitative reverse transcrip-
tase PCR (qRT-PCR) was performed on mRNA from individ-
ual rat retinas. The genes analysed were: interleukin 1β (Il1b),
chemokine (C-C motif) ligand 2 (Ccl2) and intercellular ad-
hesion molecule 1 (Icam1). Primer sequences are presented in
ESM Table 2. Full details of the qRT-PCR methods are pro-
vided in the ESM Methods.
Electroretinography To avoid possible attenuation of the stim-
ulus due to cataract formation, scotopic electroretinograms
(ERGs) were recorded 7 weeks after diabetes induction using
an EPIC-4000 Visual Electrodiagnostic Testing System (LKC
Technologies, Gaithersburg, MD, USA). Rats were dark
adapted overnight, anaesthetised with ketamine/xylazine
(150 mg/20 mg per kg body weight) and the pupils dilated
using 1% atropine and 2.5% phenylephrine eye drops
(Chauvin Pharmaceuticals, Kingston upon Thames, UK).
Electrical responses were recorded with a DTL Plus corneal
electrode (Diagnosys, Littleton, MA, USA), with a reference
electrode placed subcutaneously in the frontal portion of the
scalp and a ground electrode in the tail. White light flashes
from a handheld Mini Ganzfeld system (CMGS–1; LKC
Technologies) were used as the light stimulus. The
photostimulator unit was calibrated to deliver 2.5 cd s/m2 at
0 dB flash intensity and scotopic measurements were recorded
with flash intensities increasing from −25 dB to +10 dB. The
ERG waveforms were recorded with a bandwidth of 0.3 to
500 Hz and sampled at 2 kHz by a digital acquisition system.
Five responses were averaged at each light intensity to obtain
a single ERG recording. The amplitudes for the a- and b-
waves were measured. The oscillatory potentials were isolated
at +10 dB stimulus intensity and the summed oscillatory po-
tential time to peak calculated.
Statistical analysis Data are presented as mean ± SEM.
Statistical analyses were performed using Prism V5.03
(Graphpad, San Diego, CA, USA). All data were checked
for normality using Kolmogorov–Smirnov tests and non-
parametric tests were applied when they did not follow a nor-
mal distribution. Two-tailed Student’s t tests were used to
compare differences between two samples. Differences be-
tween all other datasets were analysed by one-way ANOVA
with Newman–Keuls post-hoc test, Kruskal–Wallis with
Dunn’s post-hoc test or multi-way ANOVA (ACR-
scavenging ELISA and ERG data) with Bonferroni’s post-
hoc test, as appropriate.
Results
2-HDP is a potent ACR scavenger that prevents Müller cell
FDP-lysine accumulation during diabetes Until now, few
drugs capable of preventing the damaging effects of cellular
ACR and FDP-lysine accumulation have been identified.
Here, we sought to explore the potential of agents capable of
directly scavenging ACR as therapeutic agents for diabetic
retinopathy. In vitro ACR scavenging by HDZ and MESNA
was first compared with that of a range of chemicals selected
as having appropriate structures and a partition coefficient (log
P −0.4 to +5.6), suggesting they could cross physiological
barriers [18]. The drugs tested were 2-HDP, 2-HQ, DPH and
2-AP. These were mixed with 5 mmol/l ACR at three different
concentrations (1.25 mmol/l, 2.5 mmol/l and 5 mmol/l) and
formation of FDP-lysine on HSA evaluated after 1 h incuba-
tion using an ELISA-based system. All the agents tested pro-
duced reductions in FDP-lysine at each concentration tested
(Fig. 1a). The most effective scavenger of ACR at the lowest
concentration used (1.25 mmol/l) was 2-HDP (p < 0.05 vs
MESNA at this concentration), with levels of FDP-lysine sim-
ilar to those seen in the control group with no added ACR
(Fig. 1a; p > 0.05 vs no ACR). Ethanol (50%) was included
as a vehicle control for DPH and 2-HQ and had no effect on
FDP-lysine formation.
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To further confirm that 2-HDP acts as a potent ACR scav-
enger, we examined the ability of this compound to confer
protection against ACR-induced Müller cell death in vitro.
Exposure of primary mouse Müller cells for 24 h to increasing
concentrations of ACR resulted in a concentration-dependent
decrease in cell survival with an IC50 of 20 μmol/l (ESM Fig.
1a).We found that 2-HDP protected against ACR (20 μmol/l)-
induced cell death in a concentration-dependent manner
(ESM Fig. 1b). Significant protection was observed with 2-
HDP concentrations ≥40 μmol/l (ESM Fig. 1b).
Having identified 2-HDP as a potent ACR-scavenging
agent, we proceeded to investigate whether this drug is capable
of preventing Müller cell FDP-lysine accumulation during ex-
perimental diabetes in rats. Accumulation of FDP-lysine in di-
abeticMüller glia was initially confirmed by co-labelling retinal
sections from control and diabetic rats for FDP-lysine and
Fig. 1 (a) FDP-lysine detected using ELISA following conjugation with
ACR in the presence of three concentrations of different scavenging mol-
ecules (light grey bars, 1.25 mmol/l; medium grey bars, 2.5 mmol/l; black
bars, 5 mmol/l), expressed as a percentage of control (no scavenger pres-
ent; PBS+ACR; data were normalised to the first control replicate). The
scavenging molecules tested were: HDZ; MESNA; 2-HDP; 2-HQ; DPH;
and 2-AP. Experiments were carried out in triplicate; ethanol (50% etha-
nol + ACR) and samples with no added ACR (No ACR; PBS only) were
included as additional controls. (b) FDP-lysine immunolabelling (green)
on retinal cross sections of control, diabetic and 2-HDP-treated diabetic
animals; scale bar, 50 μm. Cell nuclei are counterstained with propidium
iodide (red). (c, d). Column scatter graphs showing mean pixel intensity
from regions of interest randomly selected within the ganglion cell layer-
inner limiting membrane (c) and inner plexiform layer (d). Circles, con-
trol; diamonds, diabetes; triangles, diabetes +2-HDP; n=6 retinas from six
animals in each group. *p<0.05, **p<0.01 and ***p<0.001 for the indi-
cated comparisons. GCL, ganglion cell layer; ILM, inner limiting mem-
brane; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer
nuclear layer; OPL, outer plexiform layer; PL photoreceptor layer
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GFAP as described previously [9] (ESM Fig. 2). When admin-
istered to diabetic rats in their drinking water (100 mg/l), 2-
HDP appeared to be well tolerated and had no effect on
glycaemic control, water consumption or body weight when
compared with non-treated diabetic animals (p > 0.05; Table
1). Based on recorded fluid consumption, the average daily
dose of 2-HDP was 21 mg. This substantially reduced FDP-
lysine accumulation in retinal Müller cells after 3 months’ du-
ration of diabetes (Fig. 1b–d). In animals treated with 2-HDP,
FDP-lysine antibody staining in the region of the ganglion cell
layer and inner limiting membrane was significantly less in-
tense than in the diabetic animals (p < 0.001), but it was still
higher than in the control group. This pattern was repeated in
the inner plexiform layer, where Müller cell processes were
more intensely stained with the FDP-lysine antibody in the
diabetic animals compared with control animals. This staining
was reduced in the 2-HDP-treated diabetic animals (p < 0.001).
2-HDP adduct is detectable in the retina on 2-HDP supple-
mentation We used LC-HRMS to detect the presence of 2-
HDP and related compounds in the retinas of diabetic rats
given 2-HDP in their drinking water. The chromatogram
(Fig. 2a) and mass spectrum (Fig. 2b) show the 2-HDP stan-
dard to peak at 2.54 min with an m/z of 139.10. In retinal
samples from animals treated with 2-HDP, we detected the
presence of a related compound at 4.74 min retention (Fig.
2c) and 181.11 m/z (Fig. 2d). This compound was absent from
retinas of diabetic animals not treated with 2-HDP (Fig. 2e,f).
Elemental composition analysis of this compound provided
the formula C8H13N4O, based on which a plausible structure
is shown in Fig. 2g.
2-HDP protects against Müller cell gliosis, oxidative stress and
K+ channel dysregulation To explore whether limiting ACR/
FDP-lysine accumulation using 2-HDP is capable of preventing
Müller cell dysfunction during diabetes, we began by evaluat-
ing the effects of this drug on the Müller cell gliotic response.
Diabetes had no effect on expression of the gliotic marker
GFAP in the ganglion cell layer and adjacent inner limiting
membrane (Fig. 3a,b), but clearly upregulated expression in
the retinal Müller cell fibres within the inner plexiform layer
(Fig. 3a,c). This response was attenuated by 2-HDP, as indicat-
ed by a decrease in the intensity of GFAP staining (p < 0.001)
and a small reduction in the number of GFAP-positive fibres in
the inner plexiform layer (Fig. 3a,c,d; p < 0.05).
Oxidative stress in the Müller cells also appeared to be
reduced effectively by 2-HDP. The oxidative stress marker,
HO-1 [19], was elevated in the inner retinal layers of diabetic
animals in a localisation pattern consistent with Müller glia
(Fig. 3e,g), as we have previously described [8]. Diabetes-
induced upregulation of HO-1 was significantly reduced by
2-HDP in both the ganglion cell and inner plexiform layers (p
< 0.001 for both comparisons), although staining remained
above control levels (Fig. 3e–g).
It is recognised that diabetes disturbs the localisation of
Kir4.1 channels in Müller cells [8, 20]. In the healthy retina,
Kir4.1 is expressed at the highest levels in Müller cell end-feet
at the inner limiting membrane and in perivascular regions of
the intermediate and deep capillary plexuses. In diabetes, Kir4.1
expression is lost from the perivascular and inner limitingmem-
brane regions. This is thought to disrupt Müller-cell-mediated
K+ clearance in the retina, leading to extracellular K+ accumu-
lation, excitotoxicity and impaired fluid transport [20]. We ob-
served a diabetes-induced reduction inKir4.1 immunoreactivity
in the perivascular areas and in the innermost region of the
ganglion cell layer corresponding to the inner limiting mem-
brane, as described in these previous reports [8, 20] (Fig. 4a–c).
The effects of diabetes on the distribution of Kir4.1 channels
were partially reversed in the perivascular areas and completely
reversed in the ganglion cell layer following treatment with 2-
HDP (p < 0.001 in both cases), where a significant increase in
staining was seen relative to non-diabetic control animals (Fig.
4a–c). Kir4.1 immunoreactivity in the Müller cell fibres within
the inner plexiform layer was increased in sections from diabet-
ic animals and this was unaffected by 2-HDP (Fig. 4a,d).
2-HDP regulates Müller-cell-mediated pro-inflammatory re-
sponses in the diabetic retina It has previously been demon-
strated that the pattern recognition receptor, RAGE, is upregu-
lated in retinal Müller cells after 3 months of diabetes, together
with one of its major ligands, S100B [5]. Upregulation of
RAGE and S100B has previously been linked to the activation
Table 1 Diabetes-related charac-
teristics of the three experimental
groups studied
Variable Control (n=9) Diabetic (n=7) Diabetic +2-HDP (n=7)
Daily fluid consumption (ml) 55.5 ± 2.6 228.4 ± 4.6*** 209.4 ± 5.1***
Start weight (g) 238.9 ± 7.6 227.5 ± 4.6 206.6 ± 14.6
End weight (g) 527.7 ± 14.7 219.1 ± 8.6*** 218.6 ± 13.4***
HbA1c (mmol/mol) 44 ± 13 121 ± 8*** 123 ± 15***
HbA1c (%) 6.2 ± 1.2 13.2 ± 0.7*** 13.4 ± 1.36***
Data are mean ± SEM
Fluid consumption was measured daily over 1 month for each animal
***p<0.001 vs control animals
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of microglia and the induction of Müller cell inflammatory
cytokine expression in diabetes [5, 21]. In the present work,
we observed strong upregulation of RAGE and S100B in ret-
inal Müller cells of diabetic rats (Fig. 5a–f). With the exception
of RAGE expression at the ganglion cell layer and inner lim-
iting membrane, these effects were reduced or abolished by
treatment of the animals with 2-HDP (Fig. 5a–f).
Retinal sections from diabetic animals immunolabelled
with the microglial marker IBA1 appeared to have manymore
microglia than those of control animals (Fig. 6a). The fraction
of microglia displaying an ‘ameboid’, or activated phenotype
[22], also increased from 0.355 ± 0.062 in sections from con-
trol animals to 0.534 ± 0.034 in sections from diabetic rats (p
< 0.01). Diabetic animals treated with 2-HDP still exhibited an
increase in the number of microglia present, but the proportion
of activated microglia was decreased to 0.348 ± 0.030 when
compared with untreated diabetic rats (p < 0.05; Fig. 6b,c).
In line with our observation of increased numbers of acti-
vated microglia, the inflammatory markers Ccl2, Il1b and
Icam1 were transcriptionally upregulated in the retinas of di-
abetic animals (Fig. 6d–f). Treatment of diabetic rats with 2-
HDP caused a significant reduction in the mRNA levels of
Ccl2, Il1b and Icam1 (Fig. 6d–f).
2-HDP improves retinal neurophysiological function in diabe-
tes Müller cell dysfunction is believed to contribute to al-
terations in the ERG in diabetic animals [23]. Previous stud-
ies have shown that the a- and b-waves are reduced in am-
plitude and the kinetics of the oscillatory potentials are
slowed in rat models of diabetes [24, 25]. These findings
were confirmed in the current study. Both the a- and b-
waves were significantly depressed at 7 weeks in diabetic
rats compared with control rats across a wide range of light
stimulus intensities (p < 0.001 for diabetes vs control at in-
tensities ≥−5 Db for a-wave amplitude and at all intensities
for b-wave amplitude; Fig. 7a–c). Diabetic animals treated
with 2-HDP showed a significant increase in b-wave ampli-
tude at intensities ≥−10 Db (Fig. 7a,c; p < 0.05–0.01).
Fig. 2 (a) Chromatogram of
2-HDP standard. (b) Mass
spectrogram of 2-HDP standard.
(c) Chromatogram of a retinal
sample from a diabetic rat given
2-HDP in its drinking water (100
mg/l) for 1 week. (d) Extracted
chromatogram from (c) for
139.10 m/z showing detection of
a 2-HDP-related compound
eluting at 4.74 min retention time.
(e) Chromatogram of a retinal
sample from a diabetic rat not
administered 2-HDP. (f) Extracted
chromatogram from (e) for
139.10 m/z showing the absence
of a 2-HDP-related peak. (g)
Proposed structure of the
molecule found at 4.74 min
retention, 181.11 m/z and
deduced composition of:
C8H13N4O
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Treatment with 2-HDP had no effect on the a-wave ampli-
tude. Diabetes slowed the oscillatory potentials, increasing
the summed oscillatory potential time to peak. Treatment
with 2-HDP prevented this (Fig. 7d; p < 0.01).
Fig. 3 (a) GFAP
immunolabelling (green) on
retinal cross sections of control,
diabetic and 2-HDP-treated
diabetic animals; scale bar, 50
μm. Cell nuclei are
counterstained with propidium
iodide (red). (b, c)Column scatter
graphs for the mean GFAP-
staining intensity in regions of
interest randomly selected within
the ganglion cell layer-inner
limiting membrane (b) and inner
plexiform layer (c). Circles,
control; diamonds, diabetes;
triangles, diabetes + 2-HDP. (d)
Column scatter graph showing the
mean density of GFAP-labelled
Müller cell fibres. n=6 retinas
from six animals in each group.
(e) Immunolabelling for HO-1
(green) in each of the three
groups; scale bar, 50 μm. Cell
nuclei are counterstained with
propidium iodide (red). (f, g).
Column scatter graphs for the
mean HO-1-staining intensity in
regions of interest randomly
selected within the ganglion cell
layer-inner limiting membrane (f)
and inner plexiform layer (g).
Circles, control; diamonds,
diabetes; triangles, diabetes +
2-HDP; n=6 retinas from six
animals in each group; a
minimum of two and maximum
of three retinal sections were
analysed per animal. *p<0.05 and
***p<0.001 for the indicated
comparisons. GCL, ganglion cell
layer; ILM, inner limiting
membrane; INL, inner nuclear
layer; IPL, inner plexiform layer;
ONL, outer nuclear layer; OPL,
outer plexiform layer; PL
photoreceptor layer
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Discussion
Oxidative stress results in the formation of lipid aldehydes,
which covalently bind to nucleophilic amino-acid residues
to form adducts known as advanced lipoxidation end-
products (ALE) [26]. This process has been implicated in
the pathogenesis of a range of ocular diseases, including
diabetic retinopathy (see review by McDowell et al [10]).
We have previously shown that the ACR-derived FDP-ly-
sine adduct accumulates on Müller cell proteins during di-
abetes [8, 9]. Our most recent studies suggest that this may
reflect downregulation of aldehyde dehydrogenase 1A1
(ALDH1A1) in the diabetic retina, leading to reduced alde-
hyde detoxification [27]. FDP-lysine accumulation within
Müller cells appears to contribute to the dysfunction of
these cells during the early stages of experimental diabetic
retinopathy [8, 9]. This suggests that reducing ACR levels
may mitigate against the development of retinopathy in
people with diabetes [10].
In the current study, we have explored the therapeutic po-
tential of this approach using the hydrazino compound 2-HDP.
In vitro, 2-HDP was a more potent ACR-scavenging agent
than both the anti-hypertensive parent compound, HDZ and
MESNA, a thiol-based ACR scavenger used acutely to reduce
the side effects of alkylating chemotherapeutic drugs [11]. In
our hands, it blocked ACR-induced Müller cell death in cul-
ture. In vivo, 2-HDP was capable of preventing the accumu-
lation of FDP-lysine in retinal Müller glia of diabetic rats. A
stable 2-HDP adduct was found in the retina of diabetic rats
treated with this compound. While the exact route of forma-
tion of this 2-HDP adduct remains to be elucidated, it would
be consistent with the generation of a 2-HDP–ACR adduct
subjected to oxidative decarboxylation. Supplementation with
2-HDP was associated with reduced Müller cell gliosis, oxi-
dative stress and pro-inflammatory signalling as well as im-
provements in Kir4.1 localisation and retinal neurophysiolog-
ical function.
These findings provide preclinical evidence that 2-HDP in
particular and ACR scavengers in general may offer novel
therapeutic options for diabetic retinopathy. They also support
a role for both ALEs and inflammation in the disease process.
In recent years, the importance of retinal inflammation in the
pathogenesis of diabetic retinopathy has become increasingly
clear (see recent review by Roy et al [28]). Glial-derived in-
flammatory cytokines are upregulated in people with diabetes
Fig. 4 (a) Immunolabelling for Kir 4.1 (green) shown both with and
without the red channel (propidium iodide). Perivascular distribution of
Kir4.1 in the outer and inner plexiform layers is indicated (white arrows).
This pattern was not seen in sections from diabetic animals but was partly
restored in diabetic animals treated with 2-HDP (magnified inset); scale
bar, 50 μm. (b–d) Column scatter graphs show mean stain intensity for
perivascular (b), ganglion cell layer-inner limiting membrane (c) and
inner plexiform layer (d) regions of interest. Circles, control; diamonds,
diabetes; triangles, diabetes + 2-HDP; n=6 retinas from six animals in
each group; a minimum of two and maximum of three retinal sections
were analysed per animal; **p<0.01 and ***p<0.001 for the indicated
comparisons. GCL, ganglion cell layer; ILM, inner limiting membrane;
INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear
layer; OPL, outer plexiform layer; PL photoreceptor layer
R
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[29] andMüller glia are deemed to be one of the key cell types
responsible for the upregulation of pro-inflammatory cyto-
kines in the diabetic retina [5]. Previous reports have shown
that hyperglycaemia is associated with oxidative stress and
pro-inflammatory signalling in Müller cells [5, 8, 9].
Inflammatory signalling in the diabetic retina was suppressed
by 2-HDP in the current study, supporting the hypothesis that
accumulation of ACR/FDP-lysine adducts inMüller glia plays
a significant role in the development of retinal inflammation
during diabetes. Taken together with our data on retinal alde-
hyde detoxification in diabetes [27], these findings suggest
that hyperglycaemia downregulates retinal ALDH1A1
expression, leading to ACR/FDP-lysine accumulation within
Müller cells and resulting in oxidative stress and inflamma-
tion. ACR/FDP-lysine accumulation is known to induce oxi-
dative stress through the enhancement of lipid peroxidation
reactions and the depletion of endogenous antioxidants such
as glutathione [30]. The observation that scavenging of ACR
with 2-HDP was associated with reduced expression of HO-1
is consistent with this.
The changes seen in the ERG at 7 weeks’ diabetes were
similar to those reported in other animal studies, with re-
ductions in the a- and b-waves and slowed oscillatory po-
tential kinetics [24, 25]. Inhibition of the oscillatory
Fig. 5 (a) Immunolabelling
(green) for RAGE in retinal
sections from control and diabetic
animals, and from diabetic
animals treated with 2-HDP; scale
bar, 50 μm. (b, c) Column scatter
graphs showing the mean pixel
fluorescence intensity for RAGE
in ganglion cell layer-inner
limiting membrane (b) and inner
plexiform layer (c) regions of
interest. Circles, control;
diamonds, diabetes; triangles,
diabetes + 2-HDP; n=6 retinas
from six animals in each
experimental group. (d) S100B
immunolabelling in each of the
three groups. Scale bar = 50 μm.
(e, f). Column scatter graphs
representing mean S100B-
staining intensity in regions of
interest randomly selected within
the ganglion cell layer-inner
limiting membrane (e) and inner
plexiform layer (f). Circles,
control; diamonds, diabetes;
triangles, diabetes + 2-HDP; n=6
retinas from six animals in each
group. ***p<0.001 for the
indicated comparisons. GCL,
ganglion cell layer; ILM, inner
limiting membrane; INL, inner
nuclear layer; IPL, inner
plexiform layer; ONL, outer
nuclear layer; OPL, outer
plexiform layer; PL photoreceptor
layer
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potentials is reported early in human diabetes [31, 32], and
reductions in b-wave amplitude are also seen [33], though
less consistently (for reviews, see Pescosolido et al [34] and
Tzeko and Arden [35]). Treatment of animals with 2-HDP
significantly increased b-wave amplitudes compared with
their non-treated counterparts and prevented oscillatory po-
tential slowing. Although it has been postulated that Müller
cells may contribute directly to the ERG b-wave [36], it is
now generally accepted that light-induced activity of ON-
bipolar cells is the key b-wave determinant [37, 38], while
oscillatory potentials probably reflect activity of amacrine
and ganglion cells [39]. This indicates that 2-HDP treat-
ment improves inner retinal neurophysiology, consistent
with inhibition of ACR/FDP-lysine accumulation in
Müller cells and resultant pro-inflammatory signalling. Of
course, direct effects of 2-HDP on other retinal cell types
during diabetes cannot be discounted. The fact that 2-HDP
did not alter the effects of diabetes on the a-wave amplitude
indicates that the partial normalisation of the b-wave and
oscillatory potentials most likely results from improved in-
ner retinal function and is not simply secondary to changes
in photoreceptor activity [40].
Given the wide range of transcription effects induced by
ACR in cell culture [41] it is not surprising that there is grow-
ing evidence of a therapeutic role for ACR scavengers in a
wide range of pathologies. Hydralazine and phenelzine (a hy-
drazine derivative) have been shown to reduce ACR adducts,
tissue damage and neuropathic pain behaviours in rat model of
spinal cord injury [42, 43]. N-acetyl-L-cysteine (NAC),
MESNA, mercaptamine and N-benzylhydroxylamine
(NBHA) all reduce ACR cell toxicity in vitro and acetamino-
phen liver damage in vivo inmice [44, 45], althoughNAC had
Fig. 6 (a) IBA1-immunolabelled
microglia (green) in retinal
sections. Microglia demonstrated
both dendritic and amoeboid
morphologies; scale bar, 50 μm.
(b, c) Scatter plots showing total
microglial density (b) and the
density of amoeboid microglia (c)
in sections from control animals
(circles), animals with diabetes
alone (diamonds) and diabetic
animals (triangles) treated with
2-HDP; n=6 retinas from six
animals in each experimental
group. (d–f) Column scatter
graphs summarising retinal
mRNA expression for the
inflammatory signalling
molecules Il1b (d), Ccl2 (e) and
Icam1 (f), expressed as a ratio of
expression in control tissues.
Circles, control; diamonds,
diabetes; triangles, diabetes +
2-HDP; n=6 control and diabetes
+ 2-HDP retinas from six animals;
n=7 diabetic retinas from seven
animals. *p<0.05, **p<0.01 and
***p<0.001 for the indicated
comparisons. GCL, ganglion cell
layer; INL, inner nuclear layer;
IPL, inner plexiform layer; ONL,
outer nuclear layer; OPL, outer
plexiform layer; PL,
photoreceptor layer
Diabetologia
no beneficial effects on ACR-induced lung damage in rats
[46]. Several carbonyl scavengers (bisulphite, D-penicilla-
mine, hydralazine and 1-hydrazinoisoquinoline) ameliorate
smoke-extract toxicity in cell culture and may have some pro-
tective effect against smoke-inhalation injury [47]. Of rele-
vance to the present study, NBHA, by sequestering ACR,
may prevent retinal pigment epithelial cell dysfunction in di-
abetes through a mechanism involving blockade of vascular
endothelial growth factor (VEGF)/TGF-β signalling [48, 49].
The range of scavengers and possible scavenger mechanisms
has been reviewed recently [10, 50].
In summary, the current study provides in vivo evi-
dence that treatment with the ACR scavenger 2-HDP
reduced FDP-lysine adduct formation in Müller cells,
and was associated with reduced gliosis and a more phys-
iological distribution of the Kir4.1 K+ channel in the dia-
betic retina. There was also reduced expression of a mark-
er of oxidative stress and pro-inflammatory signalling
molecules as well as reduced fractional activation of ret-
inal microglia. This suppression of recognised pathogenic
mechanisms was paralleled by improvements in retinal
function, as indicated by the ERG. Taken together, the
data suggest that the therapeutic potential of ACR scav-
engers in general, and 2-HDP in particular, merits further
investigation to determine clinical utility in treating the
retinal complications of diabetes.
Fig. 7 (a) Representative
scotopic ERG waveforms at a
range of stimulus intensities from
−25 Db to +10 Db for a control,
diabetic and 2-HDP-treated
diabetic animal. The a- and b-
waves are labelled for the control
response elicited at +10 Db. (b, c)
Summary data for a-wave (b) and
b-wave (c) amplitudes for control
(light grey), diabetic (dark grey)
and diabetic animals treated with
2-HDP (medium grey). For
clarity, only significant
differences between diabetic and
2-HDP-treated diabetic animals
are indicated (*p<0.05 and
**p<0.01 vs diabetes alone). (d)
Scatter plot showing data for
summed oscillatory potential
times (**p<0.01 for the indicated
comparisons). n=8 animals in the
control and diabetic groups and
n=7 animals in the diabetic +
2-HDP group. OP, oscillatory
potential
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